ARSI plus ADT showed a trend toward improved survival in Asian patients with metastatic hormone-sensitive prostate cancer, but results were not statistically significant. Prospective studies are needed to validate these findings.
Phase 3 PROTEUS: perioperative apalutamide plus ADT met both dual primary endpoints in high-risk localized prostate cancer, raising pCR/MRD rates to 8.9% vs 1.0% and cutting metastasis or death risk by 20%.
European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.
A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.
Phase 3 PSMAddition showed that adding 177Lu-PSMA-617 to ADT plus an ARPI improved radiographic progression-free survival in PSMA-positive mHSPC. Health-related quality of life and pain were largely maintained.
New research demonstrates that physical activity after cancer diagnosis reduces mortality risk in less common cancers and enhances circadian clock function in tumor tissue, supporting exercise as a therapeutic intervention.
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
Real-world analyses of Novartis' Pluvicto show a median PFS of 13.5 months in taxane-naive mCRPC patients, with better outcomes when used after one ARPI. Additional data indicate subsequent therapies remain effective after Pluvicto, while a separate analysis found gaps in guideline-adherent treatment for mHSPC.
Another participant with metastatic castration-resistant prostate cancer achieved undetectable PSA and negative PSMA PET after treatment with 67Cu-SAR-bisPSMA in the SECuRE trial. This marks the fifth patient to achieve undetectable disease by radiographic assessment in Clarity Pharmaceuticals' program.
A randomized trial found that men with prostate cancer treated with the GnRH agonist leuprolide experienced significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix, suggesting a biological mechanism for cardiovascular risk differences between ADT drug pathways.
